GAITHERSBURG, Md., May 24, 2024
/PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma"
or the "Company"), a global biopharmaceutical company dedicated to
discovering, developing, manufacturing, and delivering new
generations of vaccines and therapeutic biologics for infectious
diseases and cancer, today announced it is changing its legal name
from "YS Biopharma Co., Ltd." to "LakeShore Biopharma Co.,
Ltd".
Dr. David Shao, Director,
President, Co-Chief Executive Officer, and Chief Business Officer
of the Company, commented, "We have decided to change our company
name to LakeShore Biopharma to align with our global market
positioning and international brand image. This change marks one of the first steps for us to expand our
market reach, and we are eager to move forward and drive success
under our new company name."
The name change and trading symbol change will not affect any
rights of shareholders or the Company's operations and financial
position. The Company's ordinary shares and warrants will continue
to be listed on the Nasdaq. Effective with the opening of the
trading day on May 28, 2024, the
ticker symbol of the Company's ordinary shares and warrants will
change from "YS" to "LSB" and from "YSBPW" to "LSBPW",
respectively. There is no action required by the Company's current
shareholders with respect to the company name or ticker symbol
changes. The Company's CUSIP will not change in connection with the
name change.
About LakeShore Biopharma (formerly known as YS
Biopharma)
LakeShore Biopharma, previously known as YS Biopharma, is a
global biopharmaceutical company dedicated to discovering,
developing, manufacturing, and delivering new generations of
vaccines and therapeutic biologics for infectious diseases and
cancer. It has developed a proprietary PIKA® immunomodulating
technology platform and a new generation of preventive and
therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B,
Influenza, Shingles, and other virus infections. The Company
operates in China, the United States, Singapore, and the
Philippines, and is led by a management team that combines
rich local expertise and global experience in the biopharmaceutical
industry. For more information, please visit
investor.ysbiopharma.com.
Investor Relations Contact
Alyssa Li
Director of Investor Relations
Email: ir@yishengbio.com
Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: YSBiopharma.IR@icrinc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ys-biopharma-announces-name-change-to-lakeshore-biopharma-302155079.html
SOURCE YS Biopharma Co., Ltd.